Media & Resources

NEW YORK –  The International AIDS Vaccine Initiative (IAVI) is pleased to announce the renewed commitment from the United Kingdom’s Department for International Development (DFID), which has confirmed a grant to IAVI of £1 million ($1.57 million) annually for the next five years. “We are grateful to the U.K. Government for having been a long standing…

The International AIDS Vaccine Initiative (IAVI) would like to extend its best wishes to Nelson Mandela on his birthday. As the first democratically elected President of South Africa and a celebrated international humanitarian leader, Nelson Mandela has also made historic contributions to AIDS awareness in South Africa and around the world. As testament to his…

The International AIDS Vaccine Initiative (IAVI) announces the appointment of Dr. Robin Weiss as Chair of the Scientific Advisory Committee (SAC) effective July 1, 2013, to June 30, 2016. In this capacity, Dr. Weiss will also serve as the SAC representative to the IAVI Board of Directors. Dr. Weiss is Emeritus Professor of Viral Oncology…

IAVI welcomes new results demonstrating that pre-exposure prophylaxis with the antiretroviral medicine tenofovir disoproxil fumarate can almost halve the risk of HIV infection for people using intravenous drugs  In a landmark study in Thailand by the U.S. Centers for Disease Control and Prevention (CDC), in partnership with the Bangkok Metropolitan Administration and the Thailand Ministry of Public…

Accelerating Next-Generation Vaccine Development for Global Disease Prevention A group of leading scientists advocate the creation of a Human Vaccines Project to accelerate the development of next generation vaccines against major global killers such as AIDS, tuberculosis, malaria and other infectious diseases. In the current issue of the journal Science they further argue that a Human Vaccines…

On World AIDS Vaccine Day, May 18, IAVI remains as committed to the quest for an AIDS vaccine as it was in 1998, when this day of observance was established to commemorate former US President Bill Clinton’s challenge to researchers to develop a vaccine against HIV. We are as committed as we were when, 13…

The US National Institute of Allergy and Infectious Diseases (NIAID) announced today that a Phase IIb clinical trial, HVTN 505, evaluating a sequential regimen of two HIV vaccine candidates has been halted. The decision was based on the outcome of an interim analysis that indicated the regimen is not likely to prevent HIV infection or…

As Product Development Partnerships (PDPs) dedicated to the discovery, development and delivery of new global health tools, we applaud the official launch of the Global Health Innovation and Technology Fund (GHIT Fund), which was announced today in Tokyo, Japan. This new public-private partnership of the Japanese Government, the Bill &Melinda Gates Foundation and a group…